News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,225 Results
Type
Article (13907)
Company Profile (101)
Press Release (252217)
Section
Business (88276)
Career Advice (476)
Deals (15360)
Drug Delivery (67)
Drug Development (36854)
Employer Resources (49)
FDA (6319)
Job Trends (6232)
News (150672)
Policy (14071)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (452)
Accelerated approval (2)
Adcomms (7)
Allergies (33)
Alliances (23307)
ALS (36)
Alzheimer's disease (503)
Antibody-drug conjugate (ADC) (37)
Approvals (6357)
Artificial intelligence (104)
Autoimmune disease (8)
Automation (3)
Bankruptcy (149)
Best Places to Work (4404)
BIOSECURE Act (9)
Biosimilars (56)
Biotechnology (40)
Bladder cancer (19)
Brain cancer (15)
Breast cancer (74)
Cancer (586)
Cardiovascular disease (70)
Career advice (417)
Career pathing (11)
CAR-T (21)
Cell therapy (85)
Cervical cancer (4)
Clinical research (31028)
Collaboration (327)
Compensation (138)
Complete response letters (17)
COVID-19 (764)
CRISPR (19)
C-suite (117)
Cystic fibrosis (35)
Data (612)
Denatured (15)
Depression (9)
Diabetes (77)
Diagnostics (1320)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (55)
Drug pricing (63)
Drug shortages (12)
Duchenne muscular dystrophy (33)
Earnings (32154)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37591)
Executive appointments (359)
FDA (6722)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (207)
Gene editing (37)
Generative AI (9)
Gene therapy (99)
GLP-1 (345)
Government (1291)
Grass and pollen (3)
Guidances (15)
Healthcare (3635)
Huntington's disease (4)
IgA nephropathy (11)
Immunology and inflammation (34)
Indications (12)
Infectious disease (797)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (13)
Intellectual property (45)
Interviews (59)
IPO (5882)
IRA (29)
Job creations (2053)
Job search strategy (376)
Kidney cancer (6)
Labor market (10)
Layoffs (180)
Leadership (3)
Legal (3435)
Liver cancer (19)
Lung cancer (79)
Lymphoma (52)
Machine learning (1)
Management (16)
Manufacturing (142)
MASH (31)
Medical device (1295)
Medtech (1297)
Mergers & acquisitions (9665)
Metabolic disorders (246)
Multiple sclerosis (20)
NASH (14)
Neurodegenerative disease (25)
Neuropsychiatric disorders (6)
Neuroscience (676)
NextGen: Class of 2025 (1601)
Non-profit (617)
Northern California (683)
Now hiring (7)
Obesity (140)
Opinion (118)
Ovarian cancer (21)
Pain (50)
Pancreatic cancer (13)
Parkinson's disease (45)
Partnered (7)
Patents (104)
Patient recruitment (28)
Peanut (10)
People (28922)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8071)
Phase II (13119)
Phase III (11805)
Pipeline (420)
Podcasts (46)
Policy (59)
Postmarket research (1403)
Preclinical (3221)
Press Release (25)
Prostate cancer (44)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (158)
Real estate (2639)
Recruiting (17)
Regulatory (10126)
Reports (14)
Research institute (567)
Resumes & cover letters (65)
Rett syndrome (1)
RNA editing (2)
RSV (7)
Schizophrenia (35)
Series A (35)
Series B (12)
Service/supplier (3)
Sickle cell disease (31)
Southern California (698)
Special edition (6)
Spinal muscular atrophy (80)
Sponsored (6)
Startups (1631)
State (2)
Stomach cancer (3)
Supply chain (28)
The Weekly (29)
United States (6932)
Vaccines (152)
Venture capitalists (13)
Webinars (10)
Weight loss (95)
Women's health (8)
Worklife (3)
Date
Today (50)
Last 7 days (259)
Last 30 days (977)
Last 365 days (12146)
2025 (3074)
2024 (12597)
2023 (14349)
2022 (19670)
2021 (20220)
2020 (19084)
2019 (14971)
2018 (11780)
2017 (13917)
2016 (13165)
2015 (15511)
2014 (12442)
2013 (10606)
2012 (11440)
2011 (11962)
2010 (10916)
Location
Africa (318)
Alabama (13)
Alaska (1)
Arizona (54)
Arkansas (3)
Asia (20149)
Australia (2607)
California (1651)
Canada (878)
China (229)
Colorado (65)
Connecticut (65)
Delaware (53)
Europe (39460)
Florida (310)
Georgia (36)
Idaho (9)
Illinois (185)
India (15)
Indiana (129)
Iowa (1)
Japan (88)
Kansas (55)
Kentucky (12)
Maine (2)
Maryland (246)
Massachusetts (1432)
Michigan (28)
Minnesota (90)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (724)
New Mexico (7)
New York (489)
North Carolina (382)
North Dakota (2)
Northern California (683)
Ohio (53)
Oklahoma (4)
Oregon (17)
Pennsylvania (418)
Puerto Rico (8)
Rhode Island (7)
South America (504)
South Carolina (2)
Southern California (698)
Tennessee (34)
Texas (220)
Utah (33)
Virginia (70)
Washington D.C. (29)
Washington State (111)
Wisconsin (14)
266,225 Results for "aria pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer’s Disease Patients in Phase 3b study
October 29, 2024
·
11 min read
Press Releases
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
January 27, 2025
·
12 min read
Press Releases
Cortechs.ai Receives FDA 510(k) Clearance for Groundbreaking NeuroQuant 5.0 Software, Expanding Support for Quantification of ARIA-E and ARIA-H
September 3, 2024
·
3 min read
BioMidwest
Aria CV Announces First Patient Successfully Implanted with Second-Generation Pulmonary Hypertension System
Aria CV, Inc today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System as part of the ASPIRE PH clinical trial at Ascension St. Vincent Cardiovascular Research Institute in Indianapolis, Indiana.
February 27, 2024
·
3 min read
Press Releases
icometrix is proud to announce the market approval of icobrain aria, the first market-approved solution for monitoring amyloid-related imaging abnormalities (ARIA) in Alzheimer’s disease
September 4, 2024
·
7 min read
Press Releases
Cortechs.ai Receives a New NIH Grant for ARIA Detection in Alzheimer’s Disease
July 31, 2024
·
2 min read
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced positive top-line results from a pharmacokinetic study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria®.
November 29, 2023
·
8 min read
Drug Development
Aria Pharmaceuticals Secures Six Provisional Patents for Pipeline Candidates
Aria Pharmaceuticals secured six provisional patents to cover the lead drug candidates for its lupus, idiopathic pulmonary fibrosis and chronic kidney disease research programs.
August 30, 2022
·
2 min read
·
Alex Keown
Genetown
Aria Pharmaceuticals Presents Positive In Vivo Data on Lead Idiopathic Pulmonary Fibrosis Treatment Candidate
Aria Pharmaceuticals, a pharmaceutical company focused on bringing first-in-class small molecules to market, today announced that its lead candidate for idiopathic pulmonary fibrosis (IPF), TXR-1002, demonstrated significant efficacy in new preclinical research.
November 14, 2022
·
4 min read
Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced the initiation of Alvotech’s confirmatory patient study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria®.
May 4, 2023
·
8 min read
1 of 26,623
Next
